Last updated: August 21, 2026
Tramadol hydrochloride and acetaminophen is a mature, off-patent analgesic combination marketed in the United States under the former brand Ultracet and through multiple generic manufacturers. The product has limited patent-driven pricing power, no biosimilar exposure, and a declining branded revenue base. Its commercial value depends on generic volume, formulary access, controlled-substance compliance, manufacturing reliability, and demand for short-term treatment of acute pain.
The combination contains 37.5 mg of tramadol hydrochloride and 325 mg of acetaminophen per tablet. The U.S. product is indicated for the short-term management of acute pain severe enough to require an opioid analgesic when alternative treatments are inadequate [1].
What is the FDA regulatory status of tramadol hydrochloride and acetaminophen?
The U.S. Food and Drug Administration approved the tramadol/acetaminophen combination as an immediate-release oral tablet. The reference product was Ultracet, originally associated with Ortho-McNeil Pharmaceutical, a Johnson & Johnson operating company. The product is regulated as a prescription drug and is subject to opioid labeling, post-market safety requirements, and controlled-substance restrictions [1].
Tramadol is a centrally acting opioid analgesic with activity at the mu-opioid receptor and effects on norepinephrine and serotonin reuptake. Acetaminophen provides a separate non-opioid analgesic mechanism. The combination is intended to provide analgesia at lower tramadol exposure than some opioid products, but it carries risks of respiratory depression, misuse, dependence, withdrawal, seizures, serotonin syndrome, and acetaminophen-related hepatotoxicity [1].
What dosage forms and strengths are marketed?
The principal U.S. dosage form is an immediate-release tablet containing:
| Product characteristic |
Description |
| Tramadol hydrochloride |
37.5 mg per tablet |
| Acetaminophen |
325 mg per tablet |
| Route |
Oral |
| Dosage form |
Immediate-release tablet |
| Reference brand |
Ultracet |
| Primary use |
Short-term acute pain |
| Regulatory category |
Prescription controlled substance |
Extended-release tramadol products generally do not contain acetaminophen. This limits direct substitution between extended-release tramadol and the fixed-dose combination.
When does tramadol hydrochloride and acetaminophen lose exclusivity?
The product lost meaningful commercial exclusivity years ago. Generic tramadol/acetaminophen products have been available for many years, and the brand no longer controls the U.S. market through active composition or formulation exclusivity.
The original commercial protection included patents associated with tramadol and the combination product. Those rights have expired or ceased to provide an effective barrier to generic competition. The precise historical patent portfolio included patents covering tramadol chemistry, pharmaceutical compositions, and analgesic combinations, but current commercial competition is governed primarily by generic approval status rather than by the branded patent estate.
What is the Orange Book status of Ultracet?
The practical Orange Book position is that Ultracet does not have an active patent estate that prevents generic tramadol hydrochloride/acetaminophen approval. Generic applicants have relied on abbreviated new drug application pathways rather than waiting for a current branded patent barrier to expire.
The Orange Book remains the controlling source for active listed patents, reference-listed drugs, and exclusivity information. Historical Orange Book entries should be distinguished from current enforceable rights because expired patents can remain relevant to the product’s development history without creating present launch protection [2].
How many patents cover tramadol hydrochloride and acetaminophen?
No active patent portfolio appears to create a meaningful U.S. barrier for the standard 37.5 mg/325 mg immediate-release tablet. The historical estate was more important during the original product launch period than it is today.
| Patent category |
Current commercial significance |
| Tramadol active-ingredient patents |
Expired or commercially exhausted |
| Fixed-dose combination patents |
Expired or no longer blocking standard generics |
| Immediate-release tablet patents |
No material barrier to ordinary generic entry |
| Method-of-use patents |
Limited practical exclusivity |
| Manufacturing patents |
Possible process value, but not a barrier to routine generic supply |
| Device or delivery patents |
Not material for the standard tablet |
| Biosimilar-related rights |
Not applicable |
Patent risk can still arise from a newly developed abuse-deterrent formulation, modified-release product, transdermal system, or combination containing a different dose ratio. Those products would not automatically receive protection from the historical Ultracet estate.
What formulation patents protect tramadol hydrochloride and acetaminophen?
The commercial product is a conventional immediate-release tablet. Its principal formulation characteristics are well understood and readily reproduced by generic manufacturers. Standard excipient, compression, dissolution, and stability technologies generally do not provide durable market exclusivity unless they are claimed in an unexpired patent and accepted by regulators as relevant to the marketed product.
Potentially protectable future formulations include:
- Abuse-deterrent tablets designed to resist crushing, extraction, or misuse.
- Modified-release tramadol/acetaminophen systems.
- Lower-acetaminophen formulations intended to reduce liver-toxicity risk.
- Fixed-dose products with improved gastrointestinal tolerability.
- Orally disintegrating tablets or other adherence-oriented formats.
- Combination products paired with non-opioid analgesics or anti-inflammatory agents.
A formulation patent would need to provide a commercially meaningful clinical or manufacturing advantage. A patent on a narrow excipient arrangement or laboratory property may have limited value if competing products can avoid the claim without changing therapeutic performance.
Are there Paragraph IV challenges to tramadol hydrochloride and acetaminophen?
Paragraph IV litigation is no longer a central market issue for the standard combination. The major generic-entry wave occurred after the original product’s exclusivity and patent protections expired. Current generic competition is primarily an abbreviated new drug application and manufacturing issue, not an active Paragraph IV campaign against a protected reference product.
A Paragraph IV certification states that a listed patent is invalid, unenforceable, or will not be infringed. For a mature product with no blocking listed patent, applicants typically rely on Paragraph I, II, or III certifications, depending on the Orange Book record and patent status [2, 3].
Which companies manufacture generic tramadol hydrochloride and acetaminophen?
The U.S. market has historically included large generic manufacturers and contract suppliers such as:
- Amneal Pharmaceuticals
- Apotex
- Dr. Reddy's Laboratories
- Hikma Pharmaceuticals
- Par Pharmaceutical, now associated with Endo's broader generic operations
- Rising Pharmaceuticals
- Sandoz
- Sun Pharmaceutical Industries
- Zydus Pharmaceuticals
- Other FDA-approved suppliers and private-label distributors
The active supplier set changes as manufacturers enter, exit, transfer applications, or face FDA manufacturing actions. Pharmacy benefit managers and wholesalers can switch suppliers based on price, availability, quality history, and contract terms.
Which companies are challenging the branded product?
The relevant challengers are generic manufacturers rather than branded pharmaceutical companies. Because the product is mature and multiple generic versions exist, competition is no longer concentrated in one or two Paragraph IV challengers. The market operates as a multi-supplier generic segment.
What patent litigation affects tramadol hydrochloride and acetaminophen?
No major current U.S. patent litigation appears to threaten ordinary generic supply of the immediate-release combination. Historical litigation, if any, is less commercially important than current FDA compliance, manufacturing continuity, controlled-substance quotas, and product recalls.
Litigation exposure remains possible in three areas:
- Patent disputes involving a new formulation or abuse-deterrent product.
- Product-liability litigation involving opioid dependence, respiratory depression, overdose, or acetaminophen toxicity.
- Government enforcement involving controlled-substance distribution, prescribing, promotion, or monitoring.
Product-liability exposure is commercially more relevant than patent litigation for a mature tramadol combination. The FDA label carries boxed-warning-level opioid risks and warns against use with alcohol, benzodiazepines, other central nervous system depressants, and serotonergic medicines [1].
What generic entry risks exist for tramadol hydrochloride and acetaminophen?
Generic entry risk is effectively realized rather than prospective. Generic products already occupy the market, and a new applicant would face a low patent barrier but a competitive approval and supply environment.
The main risks are:
| Risk |
Commercial effect |
| Price erosion |
Reduces revenue per prescription |
| Supplier consolidation |
Can increase shortage and continuity risk |
| Controlled-substance quota limits |
May restrict inventory growth |
| FDA inspection or warning action |
Can remove a supplier from the market |
| Acetaminophen safety concerns |
Can shift prescribing toward alternatives |
| Opioid stewardship |
Reduces use in chronic and moderate pain |
| State prescribing restrictions |
Limits duration and volume |
| Formulary substitution |
Favors lowest-cost generic suppliers |
FDA opioid labeling emphasizes the lowest effective dose and shortest duration consistent with treatment goals. Tramadol is also subject to federal Schedule IV controls under the Controlled Substances Act, although state-level requirements can be stricter [1, 4].
How does the market for tramadol/acetaminophen compare with competing analgesics?
The combination competes with low-cost non-opioid and opioid products. Its principal advantage is convenience: two analgesic mechanisms in one tablet. Its disadvantages include opioid-related restrictions and the cumulative acetaminophen dose.
| Competitor |
Competitive position |
| Generic tramadol alone |
Avoids acetaminophen exposure but loses fixed-dose convenience |
| Acetaminophen alone |
Lower regulatory burden and low cost; weaker analgesia for some patients |
| Ibuprofen or naproxen |
Strong non-opioid alternatives, subject to gastrointestinal, renal, and cardiovascular risks |
| Hydrocodone/acetaminophen |
Often stronger opioid effect but higher Schedule II restrictions |
| Codeine/acetaminophen |
Alternative opioid combination with variable metabolism and safety limitations |
| Tapentadol |
Branded or higher-cost alternative with different pharmacology |
| Gabapentinoids |
Used for selected neuropathic pain, not a direct acute-pain substitute |
| Local anesthetics and regional techniques |
Compete in procedural and postoperative settings |
The combination is most defensible in short-course outpatient treatment where prescribers want an oral product that combines tramadol with acetaminophen and does not carry Schedule II status. That advantage is weaker when health systems favor non-opioid pathways or impose opioid-prescribing limits.
What is the financial trajectory for tramadol hydrochloride and acetaminophen?
The financial trajectory is mature-to-declining for branded sales and stable-to-volatile for generic volume. No meaningful branded growth thesis exists without a differentiated formulation, new indication, or new delivery technology.
Branded revenue exposure
Ultracet revenue has likely become immaterial to the original innovator relative to the company’s broader pharmaceutical portfolio. Public-company filings generally do not report standalone revenue for an off-patent product of this size. Product-level revenue therefore should not be inferred from corporate segment results.
The economic model changed after generic entry:
- Branded price premium largely disappeared.
- Wholesale acquisition cost became less relevant than generic contract pricing.
- Gross margins compressed.
- Unit volume became more important than price.
- Distribution and compliance costs remained significant.
- Promotional spending declined because the product had little protected growth opportunity.
Generic revenue outlook
Generic manufacturers can generate cash flow from the product, but the opportunity is limited by intense competition. Revenue depends on prescription volume, supplier count, reimbursement terms, and the ability to maintain uninterrupted supply.
A temporary shortage or manufacturing disruption can lift prices and volumes for remaining suppliers. That benefit is usually short-lived because other approved manufacturers can restore competition. The product is therefore better viewed as a portfolio volume asset than as a high-growth pharmaceutical franchise.
How strong is the patent estate for tramadol hydrochloride and acetaminophen?
The patent estate is weak for the conventional product. Its commercial protection is substantially exhausted, and the principal barriers are regulatory and operational.
| Dimension |
Assessment |
| Composition-of-matter protection |
Exhausted |
| Standard tablet formulation |
Weak |
| Method-of-use protection |
Limited |
| Generic substitution risk |
Very high |
| Biosimilar risk |
None |
| Manufacturing complexity |
Low to moderate |
| Controlled-substance compliance burden |
Material |
| Litigation-driven exclusivity |
Low |
| Revenue durability |
Volume-dependent |
Manufacturing intellectual property can still create advantages in yield, impurity control, stability, and supply reliability. Those advantages are usually difficult to monetize as exclusivity because generic competitors can use alternative processes.
What licensing deals affect tramadol hydrochloride and acetaminophen?
No current high-value licensing deal appears to control the ordinary U.S. generic market. Historical commercialization involved rights and corporate relationships associated with the Ultracet brand and its original sponsor. Those arrangements do not create a present market monopoly after patent expiry and generic entry.
A future licensing opportunity would have greater value if it involved:
- A clinically differentiated abuse-deterrent formulation.
- A lower-risk opioid combination.
- A pediatric or geriatric dosage form with regulatory exclusivity.
- A non-opioid replacement for tramadol.
- A manufacturing process that materially improves supply reliability.
What generic launch scenarios are likely?
The conventional product has already passed the main generic launch phase. Future scenarios are operational rather than patent-driven.
Base case
Multiple generic suppliers remain active. Prices stay low, prescription volume is broadly stable or gradually declines, and revenue tracks utilization rather than innovation.
Upside case
A supplier exits, a shortage develops, or controlled-substance capacity tightens. Remaining manufacturers gain temporary share and improved pricing.
Downside case
Opioid stewardship expands, prescribers shift toward NSAIDs or other non-opioid therapies, or acetaminophen exposure becomes a stronger concern. Prescription volume and market value decline.
Product-extension case
A company launches a differentiated formulation with new clinical or abuse-deterrent attributes. Commercial success would depend on regulatory exclusivity, payer acceptance, and the ability to avoid direct generic substitution.
What geographic coverage does the product have?
Tramadol/acetaminophen is marketed internationally under different brand names, strengths, schedules, and regulatory rules. Tramadol control varies by country. In the United States, it is Schedule IV; other jurisdictions may impose stricter opioid controls or restrict combination products.
International revenue is fragmented and usually less attractive than U.S. branded revenue because the product is mature, genericized, and exposed to local pricing controls. Geographic expansion would require country-specific registrations, controlled-substance approvals, pharmacovigilance, labeling, and distribution compliance.
Key Takeaways
- Tramadol hydrochloride/acetaminophen is a mature generic analgesic combination.
- The U.S. reference product is Ultracet, an immediate-release 37.5 mg/325 mg tablet.
- Meaningful patent and regulatory exclusivity has expired.
- The Orange Book does not provide a practical current patent barrier to standard generic entry.
- Paragraph IV litigation is not the main commercial issue.
- Biosimilar risk is irrelevant because the product is a small-molecule drug.
- Generic manufacturers compete primarily on price, supply reliability, FDA compliance, and contracts.
- Branded revenue exposure is limited and likely immaterial relative to the original sponsor’s portfolio.
- The main downside risks are opioid stewardship, acetaminophen safety, controlled-substance restrictions, and generic price erosion.
- Future value would require a differentiated formulation, abuse-deterrent technology, or a new delivery platform.
FAQs
Is tramadol hydrochloride and acetaminophen still commercially protected?
No. The standard immediate-release combination is broadly genericized, and expired historical patents do not create a current market barrier.
Is Ultracet still a growth product?
No. Ultracet is a mature brand with limited growth potential. Commercial value is concentrated in generic volume and supply contracts.
Can a generic manufacturer launch tramadol/acetaminophen without Paragraph IV litigation?
Yes. If no blocking listed patent remains, an applicant can use the appropriate ANDA certification pathway without challenging an active patent.
Does tramadol/acetaminophen qualify for biosimilar competition?
No. Biosimilars apply to biologic products. Tramadol hydrochloride and acetaminophen are chemically synthesized small molecules and compete through generic-drug pathways.
Could a new tramadol/acetaminophen formulation receive patent protection?
Yes. A novel abuse-deterrent, modified-release, pediatric, or other clinically differentiated formulation could receive patents if it satisfies patentability requirements. Protection would apply to the claimed formulation, not automatically to the ordinary immediate-release tablet.
References
- U.S. Food and Drug Administration. (2023). Ultracet (tramadol hydrochloride and acetaminophen) prescribing information.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.
- U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format of an abbreviated new drug application.
- U.S. Drug Enforcement Administration. (2024). Drug scheduling.
